Johan Broddefalk

Johan Broddefalk

Auto-generated profile, based on publicly available information

Johan Broddefalk

Medicinal Chemistry CVRM, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAnika Schick
Anika Schick
MGMarc San Jose Gracia
Marc San Jose Gracia
HHHans Christian D. Hammershøj
Hans Christian D. Hammershøj
JBJohan Broddefalk
Johan Broddefalk
PMPablo Martínez-Pardo
Pablo Martínez-Pardo
Charles S ElmoreCharles S Elmore
Charles S Elmore
Peptides constitute a well-established and rapidly expanding field in the contemporary pharmaceutical drug landscape. Studies with 14 C- or 3 H-radiolabeled analogs are the gold standard for drug development, yet access to 14 C-peptides is costly and limited to derivatization of the native structure with tags or lengthy multi-step syntheses. In this work, we report a platform that installs 14 C- or 3 H-radiolabeled lysine residues directly on solid-supported peptides. The workflow constitutes a mild, peptide-compatible hydroformylation process of allylglycine residues to generate labeled allysine, followed by reductive amination that furnishes radiolabeled lysine residues directly upon cleavage from the solid support. The hydroformylation setup can be tuned for flexible isotope introduction by using 14 CO from solid precursors and 3 H 2 from standard tritium manifolds. We show that the optimized workflow tolerates diverse sequences and enables functionalization of peptides as complex as semaglutide analogs.

5 July 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
KPKevin Pinto-Gil
Kevin Pinto-Gil
LMLeonardo De Maria
Leonardo De Maria
ANAnaïs F. M. Noisier
Anaïs F. M. Noisier
SLSusan Leung
Susan Leung
AGArthur Garon
Arthur Garon
GGGian Marco Ghiandoni
Gian Marco Ghiandoni
The pharmaceutical industry’s shift toward new drug modalities, including therapeutic peptides, modified oligonucleotides, and antibody–drug conjugates, has exposed fundamental gaps in cheminformatics infrastructure. Unlike small molecules, which benefit from mature representation standards and reliable data exchange, new modalities lack robust and interoperable systems capable of capturing their structural and chemical complexity. Drawing on our experience at AstraZeneca, we examine these challenges across peptides, oligonucleotides, and ADCs, focusing on the limitations of current approaches, particularly HELM. We show that these limitations arise from both technical constraints, as new modalities exceed the scope of purely atomistic or sequence-based representations, and organizational gaps, including unresolved standardization and governance. We argue that local solutions exacerbate fragmentation, and that vendor- and community-driven standards, open implementations, and stronger governance are required to enable standardized and interoperable chemical information systems for next-generation therapeutics.

15 April 2026 in ChemRxiv
Verified
Preprint
Open access
ANAnaïs F M Noisier
Anaïs F M Noisier
GGGian Marco Ghiandoni
Gian Marco Ghiandoni
KPKevin Pinto-Gil
Kevin Pinto-Gil
AIAbdul Ingar
Abdul Ingar
JBJohan Broddefalk
Johan Broddefalk
LBLars Brive
Lars Brive
The growing interest in studying modified and cyclic peptides is constrained by limitations in how their chemical information is encoded, represented, and analysed. Traditional sequence formats such as FASTA only allow working with linear and natural peptides. HELM and BILN formats provide more versatile and extendible notation systems for the representation of peptides with non-natural monomers or cyclic arrangements. HELM is a notation that uses a database as a source of monomers where these are defined on their structure, identifier, and attachment points. While structural representations are canonicalized using established methods, there is currently no widely accepted convention for naming peptide monomers. In this manuscript, we develop on top of the guidelines proposed by Pistoia Alliance for the naming of non-natural amino acids for their representation using HELM. Our nomenclature extends on modifications of side chains and backbone, naming of homo amino acids and peptoids, and resolves ambiguous cases using a combination of systematic and pragmatic rules.